Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TPST, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Amezalpat (TPST-1120) | Hepatocellular Carcinoma (HCC) | Phase 3 · NCT06680258 | Not yet recruiting |
| Anti-LILRB2 Monoclonal Antibody IO-108 | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Imdatifan (NKT2152) | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Muzastotug (ADG126) | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Tobemstomig | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| Tiragolumab | Advanced Liver Cancers | Phase 1/2 · NCT04524871 | Active not recruiting |
| EP2/EP4 Antagonist TPST-1495 | Solid Tumor | Phase 1 · NCT04344795 | Completed |
| Part 3 TPST-1120 | Hepatocellular Carcinoma | Phase 1 · NCT03829436 | Completed |
| Part 1 TPST-1120 | Hepatocellular Carcinoma | Phase 1 · NCT03829436 | Completed |
Also used in these trials (approved or third-party drugs, not TPST's own candidates): Atezolizumab, Bevacizumab, Tocilizumab, Pembrolizumab, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TPST holds $779,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $5.2M/quarter from operations, an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 80 · High
Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed consolidated financial statements.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TPST files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Versant Venture Capital VI, L.P. 10% owner |
Insider | 2,328,585 | 11.65% | 2024-08-08 |
| SABBY MANAGEMENT, LLC | 5%+ holder (13G) | 492,223 | 2.46% | 2025-12-31 |
| Matthew Angel CEO and President, Director, 10% owner · +732,585 options |
Insider | 231,482 | 1.16% | 2026-03-24 |
| Stephen R Brady President and CEO, Director · +800,000 options |
Insider | 46,376 | 0.23% | 2024-07-03 |
| Justin Trojanowski Corporate Controller · +78,500 options |
Insider | 22,168 | 0.11% | 2024-06-28 |
| Samuel Whiting Chief Medical Officer · +370,000 options |
Insider | 9,573 | 0.05% | 2024-07-02 |
| John W. Frederick Director · +25,000 options |
Insider | 8,000 | 0.04% | 2026-10-13 |
| William Drake Richey Director · +25,000 options |
Insider | 2,000 | 0.01% | 2026-06-04 |
Share count 19,995,358 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TPST and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →